Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...
Chris Gibson, Recursion co-founder and CEO, joins 'Squawk Box' to discuss the company's $688 million acquisition of Exscientia, the use of AI in drug discovery, and more. Got a confidential news tip?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results